GC Biopharma녹십자
006280 · KOSPI · ₩006280 · 녹십자
₩130,500▲ ₩1,400 (1.08%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 26.4% | 27.8% | 28.7% | 29.8% | 34.0% | 33.9% |
| Operating margin | 2.4% | 3.5% | 1.9% | 2.1% | 4.7% | 4.8% |
| Net margin | −2.5% | −0.2% | −1.6% | −1.6% | 3.8% | 8.0% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −1.4% | +18.5% | +3.3% | −4.9% | +11.3% | — |
| Operating income growth | −31.6% | +115.4% | −6.8% | −57.6% | +10.3% | — |
| Net income growth | −967.7% | +82.2% | +1.3% | −140.7% | −46.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −4.1% | −0.4% | −2.1% | −2.0% | 5.0% | 9.7% |
| Return on assets | −2.2% | −1.0% | −1.6% | −0.8% | 2.8% | 5.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 112.4% | 113.1% | 85.3% | 71.7% | 61.2% | 64.2% |
| Net debt to equity | 59.6% | 58.3% | 46.9% | 1.9% | 11.1% | 6.3% |
| Current ratio | 134.5% | 119.6% | 156.2% | 119.6% | 181.3% | 198.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: GC Biopharma / 녹십자 / 006280 / KRX:006280
Source: KRX statistical information